Abstract
To the Editor: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine tumor with a high incidence of nodal and distant metastases and a high mortality rate.1 Among patients with MCC, 27% to 31% present with clinically apparent nodal disease and another 16% to 38% have occult nodal metastasis determined by sentinel lymph node biopsy (SLNB).2 Although SLNB is recommended for all clinically node-negative patients with MCC, little is known regarding its use for MCC. The purpose of this study was to evaluate the factors associated with the receipt of SLNB in patients with MCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
